Dose Insider / Analyses / GLP-1 burping and reflux

Burping, Reflux and Gas on a GLP-1How Common They Are and What Helps

Updated November 20, 2026 · 19 min read · FDA labels 2026, 2025 meta-analysis, NIDDK, ACG guideline 2022

Burping, heartburn, gas and bloating are among the less common stomach reactions to GLP-1 medicines, each reported by up to 10% of people in the label trials. Belching stands out because it is so rare without the drug: 7% of adults on Wegovy 2.4 mg reported it against under 1% on placebo, and 4% to 5% on Zepbound against 1%.

7%of adults on Wegovy 2.4 mg reported belching in the label trials, against under 1% on placebo
People reporting belchingLabel trials, share of participantsWEGOVY2.4 mg7%Placebounder 1%ZEPBOUND15 mg5%Placebo1%People reporting belchingLabel trials, share of participantsWEGOVY2.4 mg7%Placebounder 1%ZEPBOUND15 mg5%Placebo1%

Belching is rare without the drug: under 1% on placebo in the Wegovy trials.

On this page

A 2025 meta-analysis of 55 placebo-controlled trials found that these medicines probably increase the risk of gastroesophageal reflux disease, by about 4 extra cases for every 1,000 people. The measures with the best support are the plain ones: smaller meals, nothing to eat for two to three hours before bed, and fewer fizzy drinks.1,2,5,8

How common each one is

The labels list five related reactions: belching (eructation), reflux (gastroesophageal reflux disease), indigestion (dyspepsia), passing gas (flatulence) and bloating (abdominal distension). These are the rows, as placebo and then the weekly doses.

ReactionWegovy 2.4 mgZepbound 5, 10, 15 mgMounjaro 5, 10, 15 mgOzempic 0.5, 1 mg
Belchingunder 1%, then 7%1%, then 4%, 5%, 5%0.4%, then 3.0%, 2.5%, 3.3%0%, then 2.7%, 1.1%
Reflux3%, then 5%2%, then 4%, 4%, 5%0.4%, then 1.7%, 2.5%, 1.7%0%, then 1.9%, 1.5%
Indigestion3%, then 9%4%, then 9%, 9%, 10%3%, then 8%, 8%, 5%1.9%, then 3.5%, 2.7%
Passing gas4%, then 6%2%, then 3%, 3%, 4%0%, then 1.3%, 2.5%, 2.9%0.8%, then 0.4%, 1.5%
Bloating5%, then 7%2%, then 3%, 3%, 4%0.4%, then 0.4%, 2.9%, 0.8%Not listed

Prescribing information, section 6.1. The first figure in each cell is placebo.1,2,3,4

Five reactions, four medicinesFDA labels
Reaction

Each medicine is shown at the highest dose in its table, next to the placebo group of the same trials. The percentages count people who reported the reaction at least once.

Two patterns are visible. Belching is rare on placebo, 1% or less on all four labels, and several times more frequent on the drug. And indigestion is the most frequent of the five, at 9% to 10% on the weight-management doses.1,2

For teenagers, the Wegovy label lists belching, reflux disease, indigestion and flatulence among the gut reactions that were more frequent on the drug than on placebo in its pediatric trial, without giving percentages.1 The nutrition advisory written for people on GLP-1 therapy files the whole group under the less common side effects of these medicines, naming dyspepsia, belching, reflux and gastritis.9

The Wegovy table has a sixth row in the same family: gastritis, an inflamed stomach lining, reported by 4% on the drug against 1% on placebo. The label notes that the row combines chronic gastritis, gastritis, erosive gastritis and reflux gastritis. On Ozempic gastritis was no more frequent than on placebo, at 0.8% on 0.5 mg, 0.4% on 1 mg and 0.8% on placebo.1,3

What counts as normal

Most of these happen to everyone, which makes "more than usual" the only useful measure. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) gives the baselines.6,7

NIDDK notes that having some gas symptoms is normal, especially during or after meals, and that swallowed air that is not belched up moves on into the intestines and is passed the other way.7

NIDDK describes heartburn as a painful, burning feeling in the middle of the chest, behind the breastbone, rising from the lower tip of the breastbone toward the throat, and regurgitation as stomach contents coming back up into the throat or mouth, with a taste of food or stomach acid.6 Its line for gas symptoms is practical: they are a problem if they occur often, bother you, or affect your daily activities.7

Why a GLP-1 does this

All four labels state that the medicine delays the emptying of the stomach.1,2,3,4 The joint nutrition advisory of four U.S. medical societies names the consequence: slower emptying leads to bloating, fullness and nausea.9 Reflux is stomach contents moving upward, and the labels themselves describe stomach contents that are still present after the fasting period before surgery, in their warning about anesthesia.1 None of the labels explains the belching.

The clearest measurement of the effect on reflux comes from pooled trials. A 2025 meta-analysis in Gastroenterology gathered 55 placebo-controlled randomized trials of GLP-1 receptor agonists with 106,395 participants. It found that the medicines probably increased the risk of gastroesophageal reflux disease, with a risk ratio of 2.19 and a 95% confidence interval from 1.48 to 3.25. In absolute terms that was 4 more cases for every 1,000 people. The authors add that the increase looked more pronounced in trials of people with overweight or obesity, of the medicines that produce more weight loss, and of higher doses, although those subgroup differences did not reach statistical significance.5

The extra cases, countedChiang 2025

The meta-analysis reports 4 more cases of reflux disease and 2 more of gallstones for every 1,000 people over the length of the trials. The calculator scales those two figures and nothing else.

There is a pull in the other direction, over a longer time. NIDDK lists being overweight or having obesity first among the things that make GERD more likely, and the 2022 guideline of the American College of Gastroenterology recommends weight loss in overweight and obese patients to improve GERD symptoms, as a strong recommendation on a moderate level of evidence.6,8 A medicine that slows the stomach and also takes off weight acts on reflux in both directions. No source here measured which effect wins in the long run.

About sulfur burps

Burps that smell of rotten eggs are widely discussed by people taking these medicines. The sources have little on them. The labels count belching as one reaction and say nothing about smell. NIDDK mentions smell only for gas passed the other way: the unpleasant odor of flatus may be due to sulfur.7 It explains where intestinal gas comes from, which is the nearest thing to a mechanism: bacteria in the large intestine break down carbohydrates that the stomach and small intestine did not fully digest, and create gas in the process.7

We found no trial or label that measured how often sulfur-smelling burps occur on a GLP-1, what causes them, or what treats them, so this page does not give numbers for them. What can be said is that they fall under two headings the sources do cover, belching and gas, and that NIDDK's advice for both starts with the same steps. NIDDK also says to talk with a doctor when gas symptoms change suddenly or come with abdominal pain, constipation, diarrhea or weight loss.7

Reflux at night: the gap between dinner and bed

Two of the measures with guideline support concern the evening, and both follow from a stomach that empties slowly.

From dinner to bedNIDDK, ACG 2022
Measure against

The guidance was written for reflux in general. No source gives a different figure for people on a GLP-1, whose stomach empties more slowly.

The Zepbound and Mounjaro labels say the delay in stomach emptying is largest after the first dose and diminishes over time, and all the labels report that most stomach reactions come during dose escalation.2,4 The same evening routine may therefore work less well in the first weeks after a dose increase.

What to change in a meal

The sources give two separate lists, one for reflux and one for gas, and they overlap less than one might expect.

For reflux. NIDDK names the foods and drinks commonly linked to GERD symptoms: acidic foods such as citrus fruits and tomatoes, alcoholic drinks, chocolate, coffee and other sources of caffeine, high-fat foods, mint, and spicy foods. It does not tell everyone to avoid all of them. It says some people find that certain foods trigger their symptoms, and that a doctor may recommend reducing or avoiding them to see whether symptoms improve.6 The gastroenterology guideline takes the same line and suggests avoiding "trigger foods" for symptom control, as a conditional recommendation.8 The nutrition advisory for GLP-1 therapy adds that alcohol may worsen nausea and reflux on these medicines and should be minimized.9

For belching. NIDDK traces much belching to swallowed air and lists what increases it: chewing gum or sucking on hard candy, drinking carbonated drinks, eating or drinking too fast, smoking, and loose-fitting dentures. Its advice follows from the list, with two additions: avoid drinking with a straw, and avoid talking while eating or drinking. Eat more slowly and, when you can, sit down to eat.7

Smoking is on both lists. NIDDK counts smoking, and regular exposure to secondhand smoke, among the things that make GERD more likely, and smoking among the habits that make a person swallow more air. Quitting is one of the lifestyle changes it names for reflux, and the guideline suggests avoiding tobacco products for people with GERD symptoms.6,7,8

For gas and bloating. The second source of gas is bacteria in the large intestine breaking down carbohydrates that were not fully digested higher up. NIDDK's examples of foods and drinks that may lead to excess gas:7

NIDDK adds that some people have more gas when they consume too much fiber, and others when they eat high-fat foods, which can increase bloating. For all three problems it recommends eating smaller, more frequent meals instead of larger ones.7

That gas list collides with the advice for constipation on the same medicines, where beans, whole grains, fruit and fiber are the first step. NIDDK's answer for gas is a diary of what you eat and drink and of your symptoms, so that the foods that cause trouble for you can be told from the ones that do not.7 Our page on constipation on a GLP-1 covers the other side of the trade.

What was in the mealNIDDK
It included
And I

Log meals and symptoms in the app and the diary NIDDK recommends keeps itself.

Open the app

The lists are NIDDK's examples for reflux and for gas in general. Being on a list does not mean a food causes symptoms for you; NIDDK's own advice is to keep a diary and see which ones matter.

How strong the evidence is for each measure

Not every piece of advice rests on the same footing. The gastroenterology guideline grades its recommendations for reflux, and NIDDK's advice on gas is ungraded patient guidance.7,8

MeasureForBacking
Weight loss in people with overweight or obesityRefluxACG: strong recommendation, moderate evidence
No meals within 2 to 3 hours of bedtimeReflux at nightACG: conditional, low evidence
Raising the head of the bedReflux at nightACG: conditional, low evidence
Avoiding tobaccoRefluxACG: conditional, low evidence
Avoiding personal trigger foodsRefluxACG: conditional, low evidence
A PPI taken 30 to 60 minutes before a mealRefluxACG: strong recommendation, moderate evidence
Less swallowed air: no gum, fizzy drinks or straws, slower mealsBelchingNIDDK guidance
Smaller, more frequent mealsGas and bloatingNIDDK guidance

ACG clinical guideline 2022; NIDDK, Gas in the Digestive Tract.7,8

The guideline cites a meta-analysis suggesting that weight loss in overweight patients, not eating before going to sleep, and stopping smoking are effective in relieving GERD symptoms.8 The first of those is what a GLP-1 medicine does, which is the long-term pull mentioned above.

Medicines for reflux and gas

NIDDK describes three kinds of medicine for reflux, all sold over the counter.6

The gastroenterology guideline adds two details about PPIs. It recommends taking a PPI 30 to 60 minutes before a meal and not at bedtime, as a strong recommendation. And for people whose classic symptoms respond to an 8-week trial, it recommends attempting to discontinue the PPI afterwards.8 NIDDK's rule for all of them is that symptoms that will not go away with over-the-counter medicines are a reason to talk with a doctor.6 Doses are on the package label and are not given here.

Surgery exists for reflux that does not improve with lifestyle changes and medicines. NIDDK describes fundoplication, in which the top of the stomach is sewn around the end of the esophagus, as the most common operation and says it leads to long-term improvement in most cases. It adds that complications are more likely from surgery than from medicines.6 None of that is specific to people on a GLP-1, and for reflux that began with the injection the first conversation is about the injection.

For gas, NIDDK says doctors may recommend over-the-counter medicines, or supplements such as lactase products for lactose intolerance, depending on which symptoms a person has and whether a health condition is behind them. It advises talking with a doctor before using supplements or probiotics.7

One point is specific to these injections. Because the stomach empties more slowly, each label warns that the absorption of medicines taken by mouth at the same time may be affected.1,2,3,4 That is a reason to mention any regular reflux medicine to the prescriber of the GLP-1, and the reverse.

Does the dose matter?

Less than for nausea. On Zepbound, belching was reported by 4% on 5 mg and 5% on both higher doses, reflux by 4%, 4% and 5%, and indigestion by 9%, 9% and 10%. On Mounjaro and Ozempic the figures do not rise in step with the dose at all.2,3,4 The pooled trials hint that higher doses carry more reflux, without reaching statistical significance.5

The labels still leave room to slow down when a dose is not tolerated. The Wegovy label says the prescriber can consider delaying the next step for four weeks, and the Zepbound label allows a lower maintenance dose.1,2 These are decisions for the prescriber.

Other causes worth ruling out

Reflux and gas are common without any injection, and several causes sit alongside the medicine.

For reflux. NIDDK lists the factors that weaken the valve between the esophagus and the stomach: being overweight or having obesity, being pregnant, and smoking or inhaling secondhand smoke. It names medicines that can cause GERD or make it worse: benzodiazepines, calcium channel blockers used for high blood pressure, certain asthma medicines, nonsteroidal anti-inflammatory drugs and tricyclic antidepressants. A hiatal hernia can also increase the chance of GERD.6

For gas. NIDDK names health conditions that cause more gas or more gas symptoms: irritable bowel syndrome and other functional disorders, including functional constipation and functional dyspepsia, and problems digesting certain carbohydrates.7 Constipation is itself a common reaction to these medicines, so gas that arrives with it may ease when the constipation does.

The guideline describes what happens when reflux does not settle. For classic symptoms of heartburn and regurgitation without alarm signs, it recommends an 8-week trial of a PPI once a day before a meal. Endoscopy is recommended as the first test for people with trouble swallowing or other alarm symptoms, which it names as weight loss and bleeding from the digestive tract.8 Weight loss as an alarm sign is hard to read on a medicine prescribed to cause it, which is one more reason to tell the doctor evaluating reflux about the GLP-1.

When it is more than a side effect

NIDDK says to see a doctor if you think you have GERD, or if symptoms do not get better with over-the-counter medicines or lifestyle changes. It lists symptoms that could be related to complications of GERD or to other serious health problems:6

Two of these are what the medicine is meant to do, a smaller appetite and a falling weight, so on a GLP-1 they carry less information by themselves and more when they come with trouble swallowing or vomiting. Chest pain is different. NIDDK's page on indigestion says to see a doctor right away for pain in the chest, jaw, neck or arm, or for shortness of breath, because they may point to a more serious condition.11

For gas symptoms NIDDK's threshold is lower and less urgent: talk with your doctor if they bother you, if they change suddenly, or if they come with abdominal pain, constipation, diarrhea or weight loss.7

There is also a condition that looks like a bad case of all five reactions together. NIDDK's symptoms of gastroparesis include feeling full soon after starting a meal, too much bloating, too much belching, heartburn, nausea and vomiting.10 All four labels say the medicine is not recommended in people with severe gastroparesis.1,2,3,4 Our page on Ozempic and gastroparesis covers what is known.

Heartburn or gas, plus what?NIDDK
Along with reflux or belching I have
Or

The lists are NIDDK's for reflux and for gas in general. A page cannot examine you. For pain in the chest, jaw, neck or arm, NIDDK says to see a doctor right away.

Before surgery or sedation

Every label carries a warning that bears on reflux. There have been rare reports, after approval, of pulmonary aspiration in people on GLP-1 medicines who were having procedures under general anesthesia or deep sedation and who had residual stomach contents despite following the fasting instructions. The labels say the data are insufficient to recommend changing the fasting period or pausing the medicine, and they tell patients to inform their providers before any planned surgery or procedure.1,2,3,4 Someone with frequent reflux or regurgitation on the medicine has one more thing to mention at that conversation.

Short answers to common questions

Does Ozempic cause burping?

In a small share of people. Belching was reported by 2.7% on 0.5 mg and 1.1% on 1 mg in the label trials, and by no one on placebo.

How common is burping on Wegovy and Zepbound?

7% on Wegovy 2.4 mg against under 1% on placebo, and 4% to 5% on Zepbound against 1%.

Do GLP-1 medicines cause acid reflux?

Probably, a little. Pooled randomized trials found a risk ratio of 2.19 for reflux disease, which is 4 more cases for every 1,000 people. On the labels reflux was reported by 5% on Wegovy against 3% on placebo.

Why do I get sulfur burps?

No label or trial here measured them. NIDDK attributes the odor of intestinal gas to sulfur and its production to bacteria breaking down undigested carbohydrates.

What helps the burping?

NIDDK's advice is to swallow less air: no gum, hard candy, fizzy drinks or straws, and slower meals eaten sitting down. Smaller, more frequent meals help with gas of both kinds.

What helps the reflux at night?

Finishing meals two to three hours before lying down and raising the head 6 to 8 inches. Both are in NIDDK's guidance and the gastroenterology guideline.

Can I take an antacid or a PPI with a GLP-1?

NIDDK describes antacids, H2 blockers and PPIs as the over-the-counter options for reflux in general. The GLP-1 labels note that slower stomach emptying may affect the absorption of medicines taken by mouth, so tell the prescriber what you take.

Will it go away?

None of the sources followed these five reactions over time. The labels say that most stomach reactions come during dose escalation, and the tirzepatide labels say the slowing of the stomach diminishes over time.

When should I worry?

See a doctor for trouble swallowing, persistent vomiting, blood in vomit or stool, or reflux that does not respond to over-the-counter medicine. For pain in the chest, jaw, neck or arm, NIDDK says to see a doctor right away.

How this page was built

Every number was read in its source on November 20, 2026. The rates of the five reactions come from the current prescribing information of the four medicines. The pooled result for reflux disease comes from the abstract of a 2025 meta-analysis of 55 randomized trials. The baselines, the lists of foods and habits and the medicines come from NIDDK's pages on reflux (last reviewed July 2020) and on gas in the digestive tract (June 2021). The strength of each recommendation comes from the full text of the 2022 American College of Gastroenterology guideline on GERD, which does not mention GLP-1 medicines.

The limits are these. The labels do not report how long these reactions lasted, when they started, or how they smelled. The NIDDK guidance and the guideline were written for reflux and gas in general, and no source here tested any remedy in people taking a GLP-1. The meal checker repeats NIDDK's example lists and cannot know what triggers symptoms in a particular person. This page does not suggest doses of any medicine.

Sources

  1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1 and 7. accessdata.fda.gov
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1, 7 and 12. accessdata.fda.gov
  3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.1 and 7. accessdata.fda.gov
  4. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.1, 7 and 12. accessdata.fda.gov
  5. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
  6. National Institute of Diabetes and Digestive and Kidney Diseases. Acid Reflux (GER and GERD) in Adults: Definition and Facts; Symptoms and Causes; Treatment; Eating, Diet, and Nutrition. Last reviewed July 2020, read November 20, 2026. niddk.nih.gov
  7. National Institute of Diabetes and Digestive and Kidney Diseases. Gas in the Digestive Tract: Definition and Facts; Symptoms and Causes; Treatment; Eating, Diet, and Nutrition. Last reviewed June 2021, read November 20, 2026. niddk.nih.gov
  8. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117:27-56. doi:10.14309/ajg.0000000000001538
  9. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
  10. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Gastroparesis. Last reviewed January 2018, read November 20, 2026. niddk.nih.gov
  11. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Indigestion. Last reviewed March 2025, read November 20, 2026. niddk.nih.gov

Related analyses

Log meals, doses and symptoms together, and see which evenings go wrong.

Open Dose Insider